Previous 10 |
home / stock / hluyy / hluyy news
Alder BioPharmaceuticals (NASDAQ: ALDR ) announced on Monday (September 16) that it has struck a deal to be acquired by Lundbeck A/S (OTC Pink: HLUYY ) in a US$2 billion takeover. The Denmark-based company’s move to acquire Alder BioPharma puts Lundbeck in a position to potentially ...
The core business of Denmark's H. Lundbeck ( HLUYY ) (LUN.KO) is more or less an "is what it is" situation; while there is still some potential upside from the company's newer portfolio of drugs, potential market-expanding studies won't read out for years. Where the upside likely lies today ...
Danish pharmaceutical company H. Lundbeck ’s ( OTCPK:HLUYY ) (LUN.KO) first quarter is likely to be pretty much par for the course for the near term – double-digit growth from its portfolio of newer offsets that can’t offset the generic erosion of its old portfolio, with ...
Minerva Neurosciences ( NERV ) is set to report data from multiple clinical trials in 2019 but roluperidone, which NERV is developing as a treatment for the negative symptoms of schizophrenia, is likely to get a disproportionate amount of attention. NERV and others developing in the negative...
Group Aims to Bring Disease-Associated Biomarker Through FDA’s Drug Development Tools Qualification Program The ERP Biomarker Qualification Consortium was launched today by pharmaceutical industry members with the goal of qualifying event-related potential (ERP) biomarkers to...
On January 7, 2019, Axsome Therapeutics ( AXSM ) announced results from an 80-patient trial of bupropion vs AXS-05 (bupropion with dextromethorphan) in major depressive disorder ((MDD)). I recently wrote about results from the trial and the five additional upcoming catalysts for AXSM. Compar...
Health Canada Approves Otsuka and Lundbeck's REXULTI® (brexpiprazole) as Adjunctive Treatment of Major Depressive Disorder Canada NewsWire MONTREAL, Feb. 22, 2019 MONTREAL , Feb. 22, 2019 /CNW Telbec/ - Otsuka Pharmaceutical Canada Inc. (Otsuka) and Lundbeck Can...
Introduction - Teva ( TEVA ) versus branded biotechs TEVA reported Q4 and full-year numbers last week, and the stock sank sharply, with its ADS closing at $17.98 Friday. Using the 1.10 B fully diluted shares the company guided for the present period on the c onference call , that puts its ...
The next few years are going to seriously challenge the skills of H. Lundbeck ’s ( OTCPK:HLUYY ) (LUN.KO) recently-hired CEO Deb Dunsire and head of R&D Johan Luthman, as the company has to contend with serious erosion in its mature portfolio, a very weak late-stage pipeline (not t...
News, Short Squeeze, Breakout and More Instantly...
H Lundbeck A/S S/Adr Company Name:
HLUYY Stock Symbol:
OTCMKTS Market:
Despite supply chain disruptions and labor shortages, the pharma industry is well-positioned to continue growing due to the increasing medical needs of an aging population and advancements in treating chronic diseases. Therefore, amid current market volatility, we believe it could be wise to ...
The pharmaceutical sector received much investor attention amid the COVID-19 pandemic and their interest in this sector is expected to continue given the growing demand for pharmaceutical products and solutions. As such, we think it could be smart to bet on relatively undervalued pharma stock...
COPENHAGEN, Denmark , Aug. 31, 2020 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced headline results from the parallel group, double-blind, randomized, placebo-controlled RELIEF study [i] that assessed the efficacy and tolerability of Vyepti when initiated during a migrain...